← Back to Search

Hormone Therapy

Treatment (exemestane) for Breast Cancer

Phase 2
Waitlist Available
Led By George Somlo, MD
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up until disease progression of death from any cause, up to 3 years
Awards & highlights
Approved for 5 Other Conditions
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane may fight breast cancer by lowering the amount of estrogen the body makes. PURPOSE: This phase II trial is studying how well exemestane works in treating postmenopausal women with stage IV breast cancer.

Eligible Conditions
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~until disease progression of death from any cause, up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and until disease progression of death from any cause, up to 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Progression-free Survival
Secondary study objectives
Overall Response Rate

Awards & Highlights

Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (exemestane)Experimental Treatment4 Interventions
Patients receive oral exemestane once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Exemestane
FDA approved
quality-of-life assessment
2012
Completed Phase 3
~2780

Find a Location

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor
598 Previous Clinical Trials
1,923,340 Total Patients Enrolled
42 Trials studying Breast Cancer
6,541 Patients Enrolled for Breast Cancer
National Cancer Institute (NCI)NIH
13,879 Previous Clinical Trials
41,013,210 Total Patients Enrolled
945 Trials studying Breast Cancer
1,543,977 Patients Enrolled for Breast Cancer
George Somlo, MDPrincipal InvestigatorCity of Hope Medical Center
10 Previous Clinical Trials
513 Total Patients Enrolled
6 Trials studying Breast Cancer
390 Patients Enrolled for Breast Cancer
~2 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top